All News

Five-year follow-up data from the phase 3 SOLO-1 trial demonstrates a nearly five-year delay in disease progression with Lynparza compared with a delay of just over a year with placebo in women with newly diagnosed, advanced ovarian cancer harboring a BRCA gene mutation.

New guidance from the Food and Drug Administration recommends that the makers of breast implants include a black-box warning, a patient decision checklist and other information on product labels that will help protect them against a cancer and an autoimmune condition that can arise from use of the devices.

A woman shares her late husband’s journey with advanced penile cancer to help others receive a diagnosis early, when the disease is still highly treatable and even curable.

On social media, CURE® recently asked its readers to share how an oncology nurse has helped them on their cancer journey.

After enjoying visits from therapy dogs during treatment for testicular cancer, a student pilot decides to volunteer to transport pets needing rescue, shelter or adoption.

A weekly high dose of chemotherapy did not improve survival for patients with epithelial ovarian cancer, though the treatment regimen was effective and well-tolerated.

Forward Momentum, a coalition launched by a biopharmaceutical company and three partners, focuses on the health disparities faced by Black men with prostate cancer.

Oncology nurses have the power to heal, and in many cases, the power to inspire their patients no matter their age.

Mary Schueller devoted her entire career to helping others with cancer, and the devotion she displayed to that cause is what makes her an extraordinary healer.

In this special hematology focused issue of CURE® we look at all the promising treatments and research for both adults and children with blood cancers.

Mantle Cell Lymphoma (MCL), as described in this issue of CURE®, has an interesting and inspiring story. It was one of the first cancers known to have a genetic abnormality-chromosomal translocation t(11;14).

From a new study showing that the iCanQuit smoking cessation app is more likely to work than typical guidelines, to the House unanimously passing the Veteran’s Prostate Cancer Treatment and Research Act, here’s what’s happening in the cancer landscape this week.

Oncology nurses are there for many moments on the cancer journey and can help champion important milestones that might otherwise go by unnoticed.

Finding the best care team can make all the difference for patients with diseases like multiple myeloma.

Clinical trials lead to new cancer treatments — and can give a patient access to effective drugs years before they’re made available to the public.

In this week’s episode of the CURE® Talks Cancer podcast, we chat with Dr. Tanja Gruber, the chief of pediatric hematology, oncology and stem cell transplantation at Stanford Children’s Health, about how pediatric cancer treatment is evolving thanks to advances in treatments like immunotherapy, and what parents should do after their child receives a diagnosis.

Here is a list of some recent trials that launched within the cancer space in September.

There is no approved treatment that targets the KRAS p.G12C mutation that drives some cancers like non-small cell lung cancer. But a recent study shows how the experimental drug sotorasib sparked responses in some patients with advanced non-small cell lung cancer that harbored the mutation.

For years, childhood blood cancers were understudied forcing patients’ treatments into a one size-fits-all approach. But new efforts are changing that.

Weighing the cost of CAR-T cell therapy in treating blood cancers is a finical burden for many patients with blood cancer.

The PARP inhibitor Lynparza reduced the risk for death by 31% in men with metastatic castration-resistant prostate cancer compared with Xtandi or Zytiga plus the corticosteroid prednisone.

Findings from a randomized phase 3 study showed that adding neoadjuvant Tecentriq to a chemotherapy regimen of Abraxane, Adriamycin and Cytoxan in patients with stage 2 or 3 triple-negative breast cancer significantly improved pathologic complete responses, compared with placebo plus chemotherapy.

Exciting advances in treatment options for patients with mantle cell lymphoma are greatly improving the outlook for long-term remissions.

CAR-T Cell therapy is expanding in the field of blood cancers, but it comes with a host of side effects patients need to look out for. One study is looking to get ahead of the side effect curve for patients about to undergo CAR-T cell therapy.

In the winning essay for the Finest Hour award, Evangelina SantaTeresa, CCRN, details how the human touch makes all the difference for award winner Elizabeth “Liz” Farrat, B.S.N., CCRN at Memorial Sloan Kettering Cancer Center.

Save the date! We invite you to join CURE for our next monthly #CureConnect Tweet Chat on Thursday, September 24, at 1 p.m. EST, when we plan on discussing living with cancer, from mental health through treatment, to cancer-related pain and beyond.

On social media, CURE® recently asked its readers to share how they deal with the cognitive dysfunction that can come about from cancer treatment.

An oncology nurse outlines ways that patients can prevent dental erosion after a vomiting episode.